share_log

Needham Maintains Buy on Biogen, Lowers Price Target to $285

Benzinga ·  Aug 5 06:12  · Ratings

Needham analyst Ami Fadia maintains Biogen (NASDAQ:BIIB) with a Buy and lowers the price target from $288 to $285.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment